Prognostic model for overall survival of head and neck cancer patients in the palliative phase

Patients with head and neck squamous cell carcinoma (HNSCC) enter the palliative phase when cure is no longer possible or when they refuse curative treatment. The mean survival is five months, with a range of days until years. Realistic prognostic counseling enables patients to make well-considered...

Full description

Saved in:
Bibliographic Details
Published in:BMC palliative care 2024-02, Vol.23 (1), p.54-54, Article 54
Main Authors: Hoesseini, Arta, Sewnaik, Aniel, van den Besselaar, Boyd N, Zhang, Jang, van Leeuwen, Nikki, Hardillo, Jose A, de Jong, Robert Jan Baatenburg, Offerman, Marinella P J
Format: Article
Language:English
Subjects:
Alcohol
Body mass index
Carcinoma, Squamous Cell
Care and treatment
Caregivers
Classification
Clinical decision making
Comorbidity
Decision-making
Diagnosis
Head & neck cancer
Head and neck cancer
Head and Neck Neoplasms - complications
Head and Neck Neoplasms - therapy
Head and Neck squamous cell cancer
Health aspects
Humans
Larynx
Marital status
Medical prognosis
Metastasis
Palliative care
Palliative treatment
Patients
Prediction
Prognosis
Prognostic factors
Proportional Hazards Models
Smoking
Squamous Cell Carcinoma of Head and Neck - therapy
Survival
Tumors
Variables
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with head and neck squamous cell carcinoma (HNSCC) enter the palliative phase when cure is no longer possible or when they refuse curative treatment. The mean survival is five months, with a range of days until years. Realistic prognostic counseling enables patients to make well-considered end-of-life choices. However, physicians tend to overestimate survival. The aim of this study was to develop a prognostic model that calculates the overall survival (OS) probability of palliative HNSCC patients. Patients diagnosed with incurable HNSCC or patients who refused curative treatment for HNSCC between January 1st 2006 and June 3rd 2019 were included (n = 659). Three patients were lost to follow-up. Patients were considered to have incurable HNSCC due to tumor factors (e.g. inoperability with no other curative treatment options, distant metastasis) or patient factors (e.g. the presence of severe comorbidity and/or poor performance status).Tumor and patients factors accounted for 574 patients. An additional 82 patients refused curative treatment and were also considered palliative. The effect of 17 candidate predictors was estimated in the univariable cox proportional hazard regression model. Using backwards selection with a cut-off P-value 
ISSN:1472-684X
1472-684X
DOI:10.1186/s12904-023-01325-y